Journal article

Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance

Suellen Nicholson, Theo Karapanagiotidis, Arseniy Khvorov, Celia Douros, Francesca Mordant, Katherine Bond, Julian Druce, Deborah A Williamson, Damian Purcell, Sharon R Lewin, Sheena Sullivan, Kanta Subbarao, Mike Catton

OPEN FORUM INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2021

Abstract

Background: Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) complements nucleic acid tests for patient diagnosis and enables monitoring of population susceptibility to inform the coronavirus disease 2019 (COVID-19) pandemic response. It is important to understand the reliability of assays with different antigen or antibody targets to detect humoral immunity after SARS-CoV-2 infection and to understand how antibody (Ab) binding assays compare to those detecting neutralizing antibody (nAb), particularly as we move into the era of vaccines. Methods: We evaluated the performance of 6 commercially available enzyme-linked immunosorbent assays (ELISAs), includin..

View full abstract

Grants

Funding Acknowledgements

This work was supported by the Victorian Department of Health and Human Services and by the Australian Government Department of Health.